{"id":"NCT04625972","sponsor":"AstraZeneca","briefTitle":"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults","officialTitle":"A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-02","primaryCompletion":"2021-04-07","completion":"2022-07-25","firstPosted":"2020-11-12","resultsPosted":"2022-10-25","lastUpdate":"2023-11-21"},"enrollment":1131,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"AZD7442","otherNames":["A combination of 2 mAbs (AZD8895 and AZD1061)"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"AZD7442","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the efficacy of AZD7442 for the post-exposure prophylaxis of COVID-19 in Adults.","primaryOutcome":{"measure":"Number of Participants With First Case of SARS-CoV-2 RT-PCR Positive Symptomatic Illness","timeFrame":"Planned to be evaluated through Day 183, however, the number of participants required was achieved 127 days after the study start date","effectByArm":[{"arm":"AZD7442","deltaMin":23,"sd":null},{"arm":"Placebo","deltaMin":17,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.212"},{"comp":"OG000 vs OG001","p":"0.044"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":57,"countries":["United States","United Kingdom"]},"refs":{"pmids":["32123347","27578435","4023479","32867706","32015507","15033648","38703336","36411267","35713300","34473343"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D8850C00003&amp;attachmentIdentifier=c35deefb-0c9a-4d5c-a910-53a4f500f0e0&amp;fileName=Redacted_Clinical_Study_report_Synopsis.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D8850C00003&amp;attachmentIdentifier=373a042b-d2b9-4e49-b28d-f4c27ee2c31e&amp;fileName=d8850c00003-csp-v6_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D8850C00003&amp;attachmentIdentifier=f6878577-9ca6-411b-8de2-e4211cd9ffe0&amp;fileName=d8850c00003-sap-v-3-1_redacted_19july_1.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":749},"commonTop":["Covid-19","Headache","Cough","Fatigue","Rhinorrhoea"]}}